[1]张建强,焦永平.脉血康胶囊与依达拉奉联合治疗对出血性脑梗死患者血清MMP-9、S100β蛋白水平和神经功能的影响*[J].陕西中医,2018,(11):1521-1523.
　Zhang Jianqiang,Jiao Yongping..The Influences of Maixuekang capsule combined edaravoneon in serum MMP-9, S-100β protein levels and nerve function in patients with hemorrhagic cerebral infarction[J].,2018,(11):1521-1523.
点击复制

脉血康胶囊与依达拉奉联合治疗对出血性脑梗死患者血清MMP-9、S100β蛋白水平和神经功能的影响*
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2018年11期
页码:
1521-1523
栏目:
临床研究
出版日期:
2018-12-31

文章信息/Info

Title:
The Influences of Maixuekang capsule combined edaravoneon in serum MMP-9, S-100β protein levels and nerve function in patients with hemorrhagic cerebral infarction
文章编号:
10.3969/j.issn.1000-7369.2018.11.009
作者:
张建强1; 焦永平2
1.河南科技大学第一附属医院神经内科（洛阳 471003）,2.河南省漯河市临颖县人民医院神经内科（漯河 462600）
Author(s):
Zhang Jianqiang; Jiao Yongping.
Department of Neurology,the First Affiliated Hospital of Henan University of Science and Technology（Luoyang 471003）
关键词:
脑梗塞/中医药疗法@依达拉奉@脉血康胶囊
Keywords:
Kay words 〖JP3〗Brain infarction/traditionalChinese medicine therapy@Edaravoneon@Maixuekang capsule
分类号:
R743.33
文献标志码:
A
摘要:
目的：探讨脉血康胶囊联合依达拉奉治疗出血性脑梗死患者的疗效及对血清基质金属蛋白酶-9(MMP-9)、S-100β蛋白水平和神经功能的影响。方法：从出血性脑梗死患者中选取76例，随机分成两组。对照组给予依达拉奉，治疗组在对照组基础上配合脉血康胶囊。对比两组患者临床疗效、血清MMP-9、S-100β水平变化、神经功能恢复情况、日常生活能力及不良反应发生率。结果：治疗组总有效率92.11%高于对照组71.05%(P＜0.05）；两组患者美国国立卫生研究院卒中量表（NIHSS）评分均下降，日常生活能力量表（ADL）评分均升高，且治疗组两项评分改善程度优于对照组(均P＜0.05)；治疗后第7 d、14 d 两组患者MMP-9、S-100β水平低于治疗前(P＜0.05)，且治疗组各个时间点均低于对照组(P＜0.05)；治疗后第3 d 两组患者S-100β水平均高于治疗前(P＜0.05)；两组患者不良反应发生率比较差异无统计学意义(P＞0.05)。结论：脉血康胶囊与依达拉奉联合治疗出血性脑梗死患者疗效显著，可明显改善患者神经功能缺损及日常生活能力，降低血清MMP-9、S-100β蛋白水平，且安全性较高。
Abstract:
Objective: To investigate the effect of Maixuekang capsule combined edaravone on hemorrhagic cerebral infarction patients and its influences on serum matrix metalloproteinase-9 (MMP-9), S-100β protein levels and nerve function.Methods: 76 cases of hemorrhagic cerebral infarction patients were selected as the research subjects, they were randomly divided into two groups.The control group was given Edaravone, and the treatment group was treated with Maixuekang capsule on the basis of the control group.The clinical efficacy, serum MMP-9 and S-100β protein levels, nerve function recovery, activity of daily living and incidence rate of adverse reactions were compared between the two groups.Results:The total effective rate of the treatment group was 92.11%, which was higher than 71.05% of the control group (P<0.05); the National Institutes of Health Stroke Scale (NIHSS) score in the two groups decreased, and the Activity of Daily Living Scale (ADL) score increased, the improvement of the two scores in the treatment group was better than that in the control group (P<0.05);the levels of MMP-9 and S-100 data in the two groups were lower than those before treatment on the 7th and 14th day after treatment (P<0.05), and the treatment group was lower than the control group at all time points (P<0.05); at third day after treatment, the levels of S-100β in the two groups were all higher than those before treatment (P<0.05); there was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).Conclusion: The combination of Maixuekang capsule and edaravone is effective in treating hemorrhagic cerebral infarction, it can significantly improve nerve function defect and daily living ability, reduce serum MMP-9 and S-100β protein levels, and has higher safety.

参考文献/References:

[1]王慧云,赵军香.补阳还五汤联合西药治疗冠心病稳定型心绞痛的疗效及对血液流变学的影响[J].现代中西医结合杂志，2016，25（10）:1089.
[2]陈小紫，张宇云. 通心络胶囊配合西药治疗冠心病心绞痛疗效观察[J].陕西中医，2017，38（10）:1368.
[3]高润霖.冠也病疾病负担-中国出路[J].中国循环杂志，2017，32(1):1-4.
[4]中华医学会心血管病学分会.慢性稳定性心绞痛诊断与治疗指南［J］．中华心血管病杂志，2007，35(3):195-206.
[5]郭小玉.基于心率变异性分析的稳定型心绞痛证候与自主神经功能关联性研究[D].中国中医科学院，2017，11-15.
[6]狄美凤,张冠英,贠建英.高血压合并冠心病患者不同中医证型与心电图的关系研究[J].中医药导报，2016，17(22)：86-88.
[7]刘雪梅，蒋红红，陈征宇.冠心病中医辨证分型与心电图关系的相关研究[J].河南中医学院学报，2009，24(4)：67-68.
[8]梅琼，曾祥法，刘松林，等. 化痰活血通络方对冠心病血脂与血液流变学影响的实验研究 [J]. 湖北中医药大学学报，2016，18（1）：30-32.
[9]辛衍璞.心脑舒通胶囊治疗稳定型心绞痛(心血瘀阻证)的临床观察[D].黑龙江中医药大学，2017，27-31.
[10]卢金婧,迟鑫姝,易松.基于复杂度的心率变异性分析研究进展[J].现代生物医学进展，2009，19(15)：2957-2959.
[11]Cardoso C R, Moraes R A, Leite N C,et al.Relationships between reduced heartrate variability and pre-clinical cardiovascular dis-ease in patients with type 2 diabetes[J].Diabetes Research and Clinical Practice,2014,106(1):110-117.
[12]陈芬燕,郭韧,张毕奎. 丹参酮Ⅱ A 的心血管药理作用研究进展[J].中国中药杂志，2015，40（9）：1649-1653.
[14]林化冰，张延明．黄芪的药理分析及临床用法探讨［J］．中医临床研究，2015，8(8)：22-24.
[15]刘光颖，张哲，李峥，等．中西医结合干预冠心病稳定型心绞痛气虚血瘀证临床疗效观察［J］．中华中医药学刊，2014，32(11)：2616-2619.

备注/Memo

备注/Memo:
*河南省自然科学基金资助项目（162300410103）
更新日期/Last Update: 2018-11-30